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Cellular and humoral mechanisms of osteoclast formation in
Ewing’s sarcoma
YS Lau1, IE Adamopoulos1, A Sabokbar1, H Giele2, CLMH Gibbons2 and NA Athanasou*,1
1Department of Pathology, Nuff ield Department of Orthopaedic Surgery, Nuff ield Orthopaedic Centre, University of Oxford, Oxford OX3 7LD, UK;
2Nuff ield Department of Surgery, Nuff ield Orthopaedic Centre, University of Oxford, Oxford OX3 7LD, UK
Cellular mechanisms that account for tumour osteolysis associated with Ewing’s sarcoma are uncertain. Osteoclasts are marrow-
derived multinucleated cells (MNCs) that effect tumour osteolysis. Osteoclasts are known to form from macrophages by both
receptor activator for nuclear factor-kB (RANK) ligand (RANKL)-dependent and -independent mechanisms. In this study, our aim has
been to determine whether tumour-associated macrophages (TAMs) isolated from Ewing’s sarcoma are capable of differentiating
into osteoclasts and to characterise the cellular and humoral mechanisms whereby this occurs. Tumour-associated macrophages
were isolated from two Ewing’s sarcomas and cultured on both coverslips and dentine slices for up to 21 days with soluble RANKL
and macrophage colony stimulating factor (M-CSF). Osteoclast formation from TAMs (CD14þ ) was evidenced by the formation of
tartrate-resistant acid phosphatase (TRAP) and vitronectin receptor (VNR)-positive MNCs, which were capable of carrying out
lacunar resorption. This osteoclast formation was inhibited by the addition of bisphosphonates. Both Ewing’s sarcoma-derived
fibroblasts and some bone stromal cells expressed RANKL and supported osteoclast formation by a contact-dependent mechanism.
We also found that osteoclast differentiation occurred when Ewing’s TAMs were cultured with tumour necrosis factor (TNF)-a in the
presence of M-CSF and that TC71 Ewing’s sarcoma cells stimulated osteoclast formation through the release of a soluble factor, the
action of which was abolished by an antibody to TNF-a. These results indicate that TAMs in Ewing’s sarcoma are capable of
osteoclast differentiation by both RANKL-dependent and TNF-a-dependent mechanisms and that Ewing’s sarcoma cells produce
osteoclastogenic factor(s). Our findings suggest that anti-resorptive and anti-osteoclastogenic therapies may be useful in inhibiting the
osteolysis of Ewing’s sarcoma.
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Rapid tumour growth and extensive bone destruction are
characteristic features of Ewing’s sarcoma of bone and can result
in bone pain and pathological fracture (Mirra, 1989; Dorfman and
Czerniak, 1998). Although the tumour osteolysis associated with
the growth of primary and metastatic tumours in bone is thought
to be mediated by osteoclasts rather than tumour cells (Quinn
et al, 1994; Clohisy et al, 1996, 2000; Clohisy and Ramnaraine,
1998), the precise cellular and humoral mechanisms that
contribute to the extensive osteolysis of rapidly growing malig-
nancies of bone, such as Ewing’s sarcoma, are unknown.
Osteoclasts are specialised, multinucleated, bone-resorbing cells
that form by fusion of circulating mononuclear precursor cells
of haematopoietic origin (Athanasou, 1996). In vitro studies have
defined the ontogeny of the osteoclast and characterised the
essential cellular and humoral factors, which are required for
osteoclast differentiation. In both mouse and man, mononuclear
osteoclast precursors circulate in the monocyte fraction and
express a monocyte/macrophage rather than a mature osteoclast
phenotype (Udagawa et al, 1990; Fujikawa et al, 1996). These
circulating precursors express RANK and their differentiation into
osteoclasts requires the presence of macrophage-colony stimulat-
ing factor (M-CSF) and involves a receptor– ligand interaction
with osteoblasts/bone stromal cells that express the membrane-
bound ligand for receptor activator for nuclear factor-kB (RANK),
ligand (RANKL) (Tanaka et al, 1993; Yasuda et al, 1998). Receptor
activator for nuclear factor-kB ligand-independent mechanisms of
osteoclast formation also exist in which cytokines, such as tumour
necrosis factor (TNF)-a, a known product of Ewing’s sarcoma
tumour cells (Rube et al, 2003), can substitute for RANKL and
induce osteoclast formation from circulating precursors (Kudo
et al, 2002).
It has been shown that TAMs isolated from carcinomas and
sarcomas, when cocultured with bone-derived stromal cells and
M-CSF, are able to differentiate into multinucleated osteoclasts
capable of extensive lacunar resorption (Quinn et al, 1998; Yang
et al, 2002). This process is RANKL-dependent and is of interest
with regard to tumour osteolysis associated with Ewing’s sarcoma
as TAMs form a significant inflammatory component of rapidly
growing malignant tumours (Bugelski et al, 1987; Walter et al,
1991; Mantovani et al, 1992; Van Ravenswaay et al, 1992).
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The pathogenic mechanisms that account for the extensive
tumour osteolysis accompanying the enlargement of rapidly
growing sarcomas, such as Ewing’s sarcoma, are unknown. In this
study, our aim has been to analyse the cellular and molecular
mechanisms which contribute to the formation of osteoclasts in
Ewing’s sarcoma. In particular, we have sought to determine
whether TAMs in Ewing’s sarcoma differentiate into osteoclasts
by a RANKL-dependent or -independent mechanism. We have also
examined whether Ewing’s sarcoma tumour cells, tumour fibro-
blasts and bone stromal cells can influence this process.
MATERIALS AND METHODS
This study was approved by the Oxford Clinical Research Ethics
Committee. All cell incubations were performed in a-minimum
essential medium (MEM) with 10% heat-inactivated fetal bovine
serum (FBS), 100 U ml1 penicillin and 10 mg ml1 streptomycin
(Gibco, Paisley, UK) (MEM/FBS). All experiments were incubated
at 371C in a humidified atmosphere of 5% CO2 and 95% air, and
carried out in triplicate, with culture medium and factors
replenished every 3– 4 days.
M-CSF, TNF-a, IL-1a, osteoprotegerin (OPG) and anti-human
TNF-a antibody were obtained from R&D Systems Europe
(Abingdon, UK), soluble RANKL was obtained from Peprotech
(London, UK), zoledronate was obtained from Novartis (Basel,
Switzerland). All experiments were carried out with factors at
the following concentrations unless otherwise specified: M-CSF
(25 ng ml1), RANKL (30 ng ml1), TNF-a (20 ng ml1), IL-1 a
(10 ng ml1), zoledronate (108 M), OPG (500 ng ml1), anti-human
TNF-a antibody (10 mg ml1).
The human Ewing’s tumour cell line TC71 was kindly provided
by Professor Boshoff (University College London, UK). Ewing’s
sarcoma tumour tissue was obtained from two cases; a 2 cm3
biopsy of the soft tissue component of a tumour of the ilium in a
14-year-old female and a 1 cm3 biopsy of the soft tissue component
of a tumour of the tibia in a 22-year-old female. Frozen and
paraffin sections of each tumour specimen were cut and processed
routinely for diagnostic histopathology. Immunohistochemistry
with monoclonal antibodies TUK4 and KP1 (Dakopatts, Glostrup,
Denmark) was carried out to determine respectively the expression
of CD14 and CD68 (monocyte/macrophage-associated antigens),
to identify the presence of TAMs in these tumours. The expression
of MIC-2 (CD99) was used to identify Ewing’s sarcoma cells using
monoclonal antibody 12E7 (Dakopatts).
Bone stromal cells were obtained from explants of cancellous
bone obtained from hip arthroplasties carried out for osteo-
arthritis in five patients (three women and two men; age range
58–71 years).
Isolation and culture of tumour-associated macrophages
from Ewing’s sarcomas
Tumour-associated macrophages were isolated as described
previously (Quinn et al, 1998). Fresh tumour tissue was digested
with Type 1 collagenase (Sigma-Aldrich, Dorset, UK) for 1 h. The
digested tissue suspension was passed through a 70 mm pore-size
cell strainer (Falcons, Becton Dickinson, Oxford, UK). The filtrate
was centrifuged at 380 g for 10 min and the cells were counted in
a haemocytometer after lysis of red blood cells with 5% (v/v) acetic
acid. A total of 1 105 cells well1 were added to ivory dentine
slices and glass coverslips in a 96-well tissue culture plate. After 2 h
incubation, the dentine slices and glass coverslips were washed
in MEM/FBS and transferred into 24-well tissue culture plates.
All cultures were maintained for 24 h and up to 21 days in the
presence of M-CSF and RANKL7zoledronate, or M-CSF, TNF-a
and IL-1a7zoledronate. Negative control cultures were main-
tained in MEM/FBS with M-CSF.
Isolation of human peripheral blood mononuclear cells
Human monocytes were obtained by density gradient centrifuga-
tion of buffy coat cell preparation (National Blood Transfusion
Service, Bristol, UK). The buffy coat preparation was mixed with
an equal volume of MEM and purified over Histopaque (Sigma-
Aldrich). After centrifugation at 600  g for 25 min, the cell layer
above the Histopaque was collected, suspended in MEM and
centrifuged at 380  g for 10 min. The cell pellet was resuspended
in MEM and centrifuged again. MEM/FBS 5 ml was then added to
the cell pellet and the number of cells counted in a haematocyto-
meter following lysis of red blood cells with 5% (v/v) acetic acid. A
total of 5 105 cells per well were plated onto dentine slices and
glass coverslips in 96-well tissue culture plates with MEM/FBS.
After 2 h incubation, the dentine slices and glass coverslips were
washed in MEM/FBS and transferred into 24-well tissue culture
plates containing MEM/FBS and M-CSF. Positive controls were set
up in the presence of M-CSF and RANKL.
Cytochemical and functional assessment of osteoclast
formation
Following incubation for 24 h and 14 days, cultures on glass
coverslips were fixed and stained cytochemically for the osteoclast-
associated enzyme tartrate-resistant acid phosphatase (TRAP)
(Minkin, 1982), and immunocytochemically with the monoclonal
antibody 23C6 (Serotec, Kidlington, Oxon, UK) for the presence of
vitronectin receptor (VNR), an osteoclast-specific antigen (Horton
et al, 1985) and with MIC-2 for the presence of the Ewing’s
sarcoma-associated antigen, CD99, using an indirect immunoper-
oxidase technique (Gatter et al, 1984). In addition, these cultures
were immunocytochemically stained with the monoclonal anti-
body TUK4 for the presence of CD14. Functional evidence of
TAM-osteoclast formation was determined by a lacunar resorption
assay system using cell cultures on dentine slices (Fujikawa et al,
1996). After 21 days incubation, the cells were removed from the
dentine slices by treatment with 0.1 M ammonium hydroxide. The
dentine slices were washed, sonicated and stained with 0.5% (v/v)
toluidine blue to reveal areas of lacunar resorption and examined
by light microscopy.
Isolation of Ewing’s sarcoma-derived fibroblasts and bone
stromal cells and co-culture with PBMCs
After enzyme digestion of the tumour, the cell pellet obtained was
resuspended in MEM/FBS and placed in a 25 cm2 tissue culture
flask; the culture medium was changed after 24-h incubation and
then at 5– 7 day intervals. These cultures, containing spindle-
shaped fibroblast-like cells, were passaged at least three times
before they were used for co-culture experiments and RNA
extraction as described previously (Lau et al, 2006).
Bone stromal cells were obtained from explants of cancellous
bone as described previously (Gundle and Beresford, 1995).
Briefly, the bone pieces were placed in MEM/FBS and cultured
until confluent in a manner similar to that described above for
Ewing’s sarcoma-derived fibroblasts. The cells were passaged at
least three times before they were used for co-culture experiments
and RNA extraction.
To determine whether Ewing’s sarcoma-derived fibroblasts or
bone stromal cells could induce osteoclast formation and to
examine if this occurred through the release of a soluble factor or
required cell–cell contact, human peripheral blood mononuclear
cells (PBMCs) were co-cultured with Ewing’s sarcoma-derived
fibroblasts (or bone stromal cells) for 21 days in the presence of
M-CSF7OPG (Lau et al, 2006). Parallel cultures were set up with
PBMCs and Ewing’s sarcoma-derived fibroblasts (or bone stromal
cells) separated by a 0.4 mm Transwells polycarbonate membrane
(Nunc, Invitrogen, Paisley, Scotland).
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Messenger RNA expression of RANKL, OPG and TRAIL
Messenger RNA (mRNA) expression of RANKL, OPG and tumour
necrosis factor related apoptosis inducing ligand (TRAIL) was
determined in TC71 cells, Ewing’s sarcoma-derived fibroblasts and
isolated cancellous bone stromal cells. Total RNA extraction was
carried out using the RNeasys mini kit (Qiagen, Hombrechtikon,
Switzerland), according to the manufacturer’s instructions. Single-
strand complementary DNA (cDNA) was synthesised from 2.0 mg
of total RNA using the SuperScripts First-Strand Synthesis System
for reverse transcriptase –polymerase chain reaction (Invitrogen,
Paisley, UK). Complementary DNA was amplified by PCR using
the primers shown in Table 1. Polymerase chain reaction products
were fractionated on 1% agarose gels, and gel pictures were
scanned with AlphaImager 2200 (Alpha Innotech Corporation, San
Leandro, CA, USA).
TC71 Ewing’s sarcoma cells: effect on osteoclast formation
TC71 cells were cultured in 25 cm2 culture flasks until confluent;
conditioned medium (CM) was then extracted after further
incubation for 48 h. A dose–response curve (0–20%) established
that 10% CM provided the optimal concentration for osteoclast
formation (Figure 4A). Subsequent experiments with human
PBMCs were set up as follows:
1. M-CSF (negative control)
2. M-CSF, RANKL (positive control)
3. M-CSF, 10% CM
4. M-CSF, 10% CM, 7OPG
5. M-CSF, 10% CM, 7anti-human TNF-a antibody
To ascertain if Ewing’s sarcoma cells are able to resorb directly
bone, parallel 21-day cultures were set up with TC71 cells seeded
onto glass coverslips and dentine slices incubated with M-CSF
alone, M-CSF and RANKL, or with no added factors.
Statistical analysis
The amount of lacunar resorption in cell cultures on dentine slices
was measured (non-blinded) using image analysis software (Adobe
Photoshop, www.adobe.com, USA) as described previously (Quinn
et al, 1998) and expressed as the mean percentage of surface area
resorbed7s.e.m. All resorption data were normalised and
expressed relative to the response obtained in PBMC cultures
incubated with M-CSF and RANKL (positive control). Statistical
significance was determined using the unpaired t-test and P-values
o0.05 were considered significant.
RESULTS
Characterisation of TAMs isolated from Ewing’s sarcoma
24-h cultures of Ewing’s sarcoma mononuclear cells on glass
coverslips in the presence or absence of RANKL and M-CSF did
not express the osteoclast markers TRAP and VNR but strongly
expressed CD14, a macrophage antigen which is known not to be
present on osteoclasts (Athanasou and Quinn, 1990; Athanasou,
1996). There was no expression of the Ewing’s sarcoma-associated
antigen, CD99. In 24-h cultures of isolated cells on dentine slices,
no evidence of lacunar resorption was noted. The mononuclear
cells isolated from Ewing’s sarcomas thus expressed only the
phenotypic characteristics of TAMs and not osteoclasts.
Ewing’s sarcoma TAM-osteoclast differentiation
Multinucleated cells (MNCs) expressing the osteoclast-associated
markers, TRAP and VNR, were found to be present in all 14-day
TAM cultures incubated with RANKL and M-CSF (Figure 1A and
B). Scattered mononuclear cells positive for CD14 were also noted
in these cultures, indicating that not all TAMs showed evidence
of osteoclast differentiation. The TRAPþ /VNRþ mononuclear
cells were also noted in these cultures; mononuclear cells that
exhibit the cytochemical and functional characteristics of osteo-
clasts have previously been noted in mouse and human macro-
phage cultures (Sterling et al, 1998; Quinn et al, 2002;
Adamopoulos et al, 2006). There was no expression of CD99. No
TRAPþ or VNRþ MNCs were seen when RANKL was omitted or
when zoledronate was added to M-CSF/RANKL-treated cultures.
The TRAPþ and VNRþ MNCs were also noted in cultures of
TAMs incubated in the presence of TNF-a and M-CSF.
Cultures of Ewing’s sarcoma TAMs incubated on dentine slices
for 21 days in the presence of M-CSF/RANKL or TNF-a/IL-1a
showed a functional evidence of osteoclast differentiation with
the formation of several areas of lacunar resorption on all dentine
slices. Resorption was evident as discrete areas of osteolysis
composed of single resorption pits (TNF-a/IL-1a-treated) or
multiple compound areas of lacunar excavation (M-CSF/RANKL-
treated) (Figure 1C) on the surface of each dentine slice. Lacunar
resorption was not seen when M-CSF or soluble RANKL was
omitted from the cultures (Figure 1D). When zoledronate was
added to M-CSF/RANKL or TNF-a/IL-1a-treated cultures, no
resorption was seen on dentine slices.
Effect of Ewing’s sarcoma-derived fibroblasts and bone
stromal cells on osteoclast formation
Fibroblasts isolated from Ewing’s sarcomas and bone stromal cells
consisted almost entirely of spindle-shaped mononuclear cells,
Table 1
Primer sequence Size of product (base pairs) Annealing temperature (1C)
GAPDH Forward: 50-CACTGACACGTTGGCAGTGG-30 ; 360 60
Reverse: 50-CATGGAGAAGGCTGGGGCTC-30 ;
OPG Forward 50- ATGAACAAGTTGCTGTGCTG-30 ; 354 58
Reverse 50-GCAGAACTCTATCTCAAGGTA-30 ;
RANKL Forward 50-CAGATGGATCCTAATAGAAT-30 ; 324 56
Reverse 50-ATGGGAACCAGATGGGATGTC-30 ;
TRAIL Forward 50-ATCATGGCTATGATGGAGGT-30 ; 315 58
Reverse 50-AACTGTAGAAATGGTTTCCTC-30
GAPDH¼ glyceraldehyde-3-phosphate dehydrogenase; OPG¼ osteoprotegerin; RANKL¼ receptor activator for nuclear factor-kB ligand; TRAIL¼ tumour necrosis factor
related apoptosis inducing ligand.
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which did not stain immunohistochemically for CD99, CD14 or
CD68 or VNR and TRAP. When CD14þ monocytes were co-
cultured with either Ewing’s sarcoma-derived fibroblasts or bone
stromal cells, in the presence of M-CSF, evidence of osteoclast
formation was noted with formation of TRAPþ and VNRþ MNCs.
In addition, co-cultures of either Ewing’s sarcoma-derived
fibroblasts or bone stromal cells and PBMCs on dentine slices
resulted in the formation of lacunar resorption pits (Figure 2A–C).
Resorption pit formation was abolished by the addition of OPG. In
transwells cultures of Ewing’s sarcoma-derived fibroblasts or bone
BA
C D
Figure 1 (A) TRAPþ and (B) VNRþ MNCs formed after 14 days when Ewing’s sarcoma-derived TAMs were cultured in the presence of RANKL and
M-CSF. (C) Extensive lacunar resorption on a dentine slice after TAMs were cultured for 21 days in the presence of RANKL and M-CSF (Toluidine blue
staining). (D) No resorption was seen on dentine in 21-day TAM cultures when RANKL was omitted (toluidine blue staining). Zoledronate-treated cultures
showed a similar appearance. Bars¼ 50 mm.
A
C
B
Figure 2 (A) TRAPþ and (B) VNRþ MNCs in a 14-day coculture of human PBMCs with Ewing’s sarcoma-derived fibroblasts in the presence of M-CSF.
(C) Lacunar resorption pits formed on a dentine slice in a 21-day coculture of human PBMCs with Ewing’s sarcoma-derived fibroblasts in similar conditions.
Bars¼ 50 mm.
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stromal cells with PBMCs, no TRAPþ or VNRþ MNCs were
formed and no lacunar resorption was noted on dentine slices.
Expression of RANKL, OPG and TRAIL mRNA
Expression of RANKL, OPG and TRAIL was noted in both Ewing’s
sarcoma-derived fibroblasts and bone stromal cells (Figure 3).
Significantly less expression of RANKL was noted in Ewing’s
sarcoma-derived fibroblasts than bone stromal cells. Reverse
transcriptase –polymerase chain reaction studies also showed that
Ewing’s sarcoma tumour cells exhibited weak expression of the
m-RNA for RANKL, OPG and TRAIL.
Effect of TC71 Ewing’s sarcoma cells on osteoclast
formation
Cultures of human PBMCs incubated with M-CSF and TC71 CM
resulted in the formation of TRAPþ and VNRþ MNCs capable of
lacunar resorption. The amount of lacunar resorption was dose-
dependent, with maximal resorption seen at CM concentration of
10% (Figure 4A). The addition of OPG or RANK: Fc to TC71 CM-
treated PBMC cultures did not abolish osteoclast formation or
significantly inhibit lacunar resorption. The addition of neutralis-
ing antibodies to TNF-a abolished lacunar resorption in TC71
CM-treated PBMC cultures (Figure 4B). Cultures of TC71 cells
alone, both in the presence and absence of M-CSF/RANKL or M-
CSF/TNF-a, did not result in the formation of TRAPþ or VNRþ
cells in cultures on glass coverslips or in lacunar resorption in
cultures on dentine slices.
DISCUSSION
This study has shown that TAMs isolated from Ewing’s sarcoma
are capable of differentiation into mature functional osteoclasts.
Mononuclear osteoclast precursors were found in the CD14þ
(macrophage) population of cells isolated from Ewing’s sarcomas
and these cells were capable of differentiating into osteoclasts
capable of lacunar resorption in the presence of RANKL and
M-CSF. Both bone stromal cells and Ewing’s sarcoma-derived
fibroblasts expressed RANKL and were capable of inducing
osteoclast formation by a contact-dependent mechanism. In the
presence of M-CSF, TAM-osteoclast differentiation was also
induced by TNF-a. Osteoclast formation was also induced by a
soluble factor produced by TC71 Ewing’s sarcoma cells. When
Ewing’s sarcoma cells were cultured directly on bone (both in the
presence and absence of M-CSF and RANKL or TNF-a), these cells
did not differentiate into osteoclasts and were not capable of
lacunar resorption.
Our findings are in keeping with the concept that tumour cells
are not capable of lacunar resorption and that osteoclasts (which
are part of the mononuclear phagocyte system) are required for
tumour osteolysis (Quinn et al, 1994; Clohisy et al, 1996; Clohisy
and Ramnaraine, 1998). Osteoclast formation was not seen in
cultures of tumour cells and was only noted in cultures that
contained Ewing’s sarcoma-derived TAMs or their monocyte
precursors (McBride, 1986; Mantovani et al, 1992). Osteoclast
formation is known to occur from the monocyte fraction of
peripheral blood mononuclear cells as well as from tissue
macrophages isolated from neoplastic and non-neoplastic lesions
(Fujikawa et al, 1996; Quinn et al, 1998; Lau et al, 2006).
Heterogeneity of monocytes and macrophages is well-recognised
and these cells are capable of differentiation into specialised cells
of the mononuclear phagocyte system (MPS), such as the
osteoclast, the specialised MPS cell of bone (Gordon and Taylor,
2005). Osteoclasts are known to have a highly specific cytochem-
ical and antigenic phenotype and are uniquely capable of lacunar
bone resorption (Athanasou, 1996). We found that TAMs isolated
from Ewing’s sarcoma did not express the osteoclast markers
TRAP and VNR, but did express CD14, a monocyte/macrophage
marker not expressed by osteoclasts. When TAMs were incubated
with M-CSF and RANKL, there was formation of numerous
TRAPþ /VNRþ MNCs that were capable of extensive lacunar
resorption.
TRAIL
OPG
RANKL
GAPDH
1 2 3 4 5 6 7 8
Figure 3 Expression of RANKL, OPG and TRAIL mRNA by fibroblasts
derived from Ewing’s sarcoma and TC71 cells. Reverse transcription-
polymerase chain reaction products were fractionated on agarose gel.
Lane 1, positive control; lane 2, negative control; lane 3, TC71; lanes
4–5, Ewing’s sarcoma-derived fibroblasts from two patients; lanes 6–8,
normal bone stromal cells.
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Figure 4 (A) % surface area (SA) resorption formed in human PBMC
cultures incubated with M-CSF and TC71 conditioned medium relative to
positive control (PBMC cultures with M-CSF and RANKL). Error bars
denote s.e.m. (n¼ 3). (B)The effect of OPG, RANK: Fc and neutralising
antibodies to TNF-a on resorption in PBMC cultures incubated with M-CSF
and 10% TC71 conditioned medium. The data represent the mean %
surface area (SA) lacunar resorption relative to the positive control (PBMC
cultures with M-CSF and RANKL). Error bars denote s.e.m. (n¼ 6).
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We found that Ewing’s sarcoma-derived fibroblasts and bone
stromal cells expressed RANKL and that these cells were capable of
inducing osteoclast formation (in the absence of soluble RANKL)
when cocultured in contact with monocyte-derived macrophages.
This process was inhibited by the addition of OPG, a decoy
receptor for RANKL. These findings indicate that this contact-
dependent process is RANKL-driven, which means that osteoclast
formation and osteolysis occurring in Ewing’s sarcoma is through
a cell–cell interaction involving RANK-expressing mononuclear
phagocyte osteoclast precursors and RANKL-expressing tumour
fibroblasts or bone stromal cells in the affected bone. Although the
low level of RANKL expression by Ewing’s sarcoma-derived
fibroblasts raises the question of how significant is the contribu-
tion of this RANKL-mediated mechanism, fibroblasts and bone
stromal cells have been shown to play a similar role in inducing
osteoclast formation in other bone tumours, such as giant cell
tumour of bone and Paget’s sarcoma, as well as in tumours known
to metastasise to bone, such as melanoma and neuroblastoma
(Michigami et al, 2001; Lau et al, 2005; Lau et al, 2006; Sun et al,
2006). Tumour fibroblasts, like bone stromal cells, have also been
shown to produce M-CSF, a survival factor for macrophages and
an essential cofactor in osteoclastogenesis (Felix et al, 1994;
Flanagan and Lader, 1998).
TNF-a is known to play a role in cell proliferation, and serum
levels of TNF-a as well as M-CSF have been correlated with the
progression of Ewing’s sarcoma (Kwon et al, 1998; Holzer et al,
2003). Tumour necrosis factor-a has been shown to play a role in
inducing osteoclast differentiation from marrow-derived circulat-
ing monocyte precursors and inflammatory macrophages (Kudo
et al, 2002; Sabokbar et al, 2003), and we found that the addition of
TNF-a (with M-CSF) to cultures of Ewing’s sarcoma-derived TAMs
induced osteoclast formation in the absence of RANKL. As Ewing’s
sarcoma cells are known to produce abundant TNF-a (Rube et al,
2003), we further investigated whether this cytokine played a role
in stimulating osteoclast formation by tumour cells. We found
that, in the presence of M-CSF and the conditioned medium of
cultured TC71 Ewing’s sarcoma cells, monocytes differentiated
into TRAPþ /VNRþ MNCs that were capable of lacunar resorp-
tion. This osteoclast formation was not inhibited by the addition of
OPG but was abolished by an antibody to TNF-a. The MNCs that
formed in these monocyte cultures were small and they produced
discrete lacunar resorption pits that were morphologically similar
to those formed in TNF-a-treated TAM cultures. As TNF-a is
known to stimulate RANKL expression and as TC71 Ewing’s
sarcoma cells expressed RANKL, it was not possible to determine
if TNF-a in the TC71 conditioned medium was directly inducing
osteoclastogenesis. It is possible that the inhibitory effect of the
TNF-a antibody on osteoclast formation may have been directed
against the known permissive effect of this cytokine on RANKL-
induced osteoclastogenesis (Lam et al, 2000). Although the soluble
factor produced by TC71 cells did not induce as much osteoclast
formation and resorption as RANKL, it could nevertheless play a
significant role in the osteolysis of a highly cellular tumour such as
Ewing’s sarcoma where there would be numerous proliferating
tumour cells producing this osteoclastogenic factor.
All the cellular and humoral elements which we have identified
as playing a role in TAM-osteoclast differentiation can be found in
the microenvironment of an osteolytic Ewing’s sarcoma of bone. It
is possible that the extent of TAM-osteoclast differentiation (and
resultant osteolysis) that occurs in a Ewing’s sarcoma is influenced
by cytokines/growth factors produced by the various cellular
components, which we have shown to influence this process. In
keeping with this hypothesis, we found that OPG, which acts as a
decoy receptor for RANK, inhibited RANKL-induced osteoclast
formation and that an antibody to TNF-a inhibited osteoclast
formation associated with the production of a soluble factor by
Ewing’s sarcoma cells. We also noted that the bisphosphonate,
zoledronate, abolished osteoclast formation and resorption by
osteoclasts produced from TAMs. Bisphosphonates are known to
inhibit osteoclast formation and resorption activity and to induce
osteoclast apoptosis (Rogers et al, 2000); bisphosphonates have
also been shown to inhibit the growth of Ewing’s sarcomas through
mechanisms that involve upregulation of osteoprotegerin (Zhou
et al, 2005). Bisphosphonates and other agents that influence
osteoclast formation and resorption activity may thus be useful in
controlling the tumour osteolysis associated with Ewing’s sarcoma.
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